	Therapy/preve Level etiology/harm	ntion, Prognosi	s Diagnosis		Economic and nptom decision tudy analyses			Leve
	3a SR (with homogeneity*) case-control stu		SR (with homogene 3b and be studies	SR (with ity*) of homogeneity* ter and better stu				1a
	3b Individual case-ostudy	control	Nonconse study; or consistent applied ret standards	vithout cohort study, ly limited popula	or very based on	level 3	level 1	1b
Level	Therapy/prevention, etiology/harm Case-series (and poor quality cohort and case-control studies ^{§§})	Prognosis Case-series (and poor quality prognostic cohort studies***)	Diagnosis Case-control study, poor or non-independent reference standards	Differential diagnosis/symptom prevalence study Case-series or superseded reference standard	Economic and decision analyses Analysis with no sensitivity analysis	level 4 levels eviden		1c
Level 5	Therapy/prevention, etiology/harm Expert opinion without explicit critical appraisal, or based on	Prognosis Expert opinion without explicit	Diagnosis Expert opinion without explicit critical appraisal,	Differential diagnosis/symptom prevalence study Expert opinion without explicit critical appraisal, or	Economic and decision analyses Expert opinion without explicit critical			2a 2b
	appraisal, or dased on physiology, bench research or "first principles"	appraisal, or based on physiology, bench research or "first principles"	or based on physiology, bench research	based on physiology, bench research or "first principles"	appraisal, or based on economic theory or "first principles"	level 5	level 2	

Level 5 evidence or troublingly inconsistent or inconclusive studies of any level

Lev	Therapy/prevention, el etiology/harm	Prognosis	Diagnosis	Differential diagnosis/symptom prevalence study	Economic and decision analyses
1a	SR (with homogeneity*) of RCTs	SR (with homogeneity*) of inception cohort studies; CDR† validated in different populations	SR (with homogeneity*) of Level 1 diagnostic studies; CDR† with 1b studies from different clinical centers	SR (with homogeneity*) of prospective cohort studies	SR (with homogeneity*) of Level 1 economic studies
1b	Individual RCT (with narrow confidence interval [‡])	Individual inception cohort study with >80%follow-up; CDR validated in a single population	Validating** cohort study with good*†† reference standards; or CDR tested within one clinical center	Prospective cohort study with good follow-up****	Analysis based on clinically sensible costs or alternatives; systematic review(s) of the evidence; and including multi-way sensitivity analyses
1c	All or none§	All or none case-series	Absolute SpPins and SnNouts ^{††}	All or none case-series	Absolute better-value or worse-value analyses ^{††††}

Leve	Therapy/prevention, letiology/harm	Prognosis	Diagnosis	Differential diagnosis/symptom prevalence study	Economic and decision analyses
2a	SR (with homogeneity*) of cohort studies	SR (with homogeneity*) of either retrospective cohort studies or untreated control groups in RCTs	SR (with homogeneity*) of Level >2 diagnostic studies	SR (with homogeneity*) of 2b and better studies	SR (with homogeneity*) of level >2 economic studies
2b	Individual cohort study (including low quality RCT; e.g., <80%follow-up)	Retrospective cohort study or follow-up of untreated control patients in an RCT; Derivation of CDR† or validated on split-sample SSS only	Exploratory** cohort study with good reference standards, CDR [†] after derivation, or validated only on split-sample§§§ or databases	Retrospective cohort study, or poor follow-up	Analysis based on clinically sensible costs or alternatives; limited review(s) of the evidence, or single studies; and including multi-way sensitivity analyses
2c	"Outcomes" research; ecological studies	"Outcomes" research		Ecological studies	Audit or outcomes research